In 2012, Duvoux et al. proposed and validated a model incorporating AFP, tumor size, and nodule number to predict post-transplant HCC recurrence: a cut-off of 2 was identified for the selection of patients with an acceptable risk of recurrence. The gene discussed is AFP; the disease is neoplasm.